Search

1121 Result(s)
Sort by

biopharmaceuticals-in-china

biopharmaceuticals-in-china

Boehringer Ingelheim manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.
CHMP_opinion_nintedanib_ILD_PF

CHMP_opinion_nintedanib_ILD_PF

Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
EFPIA disclosure

EFPIA disclosure

Disclosure of Boehringer Ingelheim affiliates in countries with EFPIA member associations.
S&P Animal Health Partnering Oct 2023

S&P Animal Health Partnering Oct 2023

Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach
1885-1948: Innovative beginnings

1885-1948: Innovative beginnings

The Boehringer Ingelheim history from its start in 1885 to 1948, with milestones and important products
How BI Supports Grass Roots Innovation

How BI Supports Grass Roots Innovation

Hear from life-science entrepreneurs about how we are supporting early-stage science through our innovative Grass Roots program.
Interview Dr Mehdi Shahidi

Interview Dr Mehdi Shahidi

Interview with Dr Mehdi Shahidi, Chief Medical Officer and Head of the Corporate Division Medicine at Boehringer Ingelheim
Valerie Nock

Valerie Nock

My career challengeFunctional Areas at Boehringer Ingelheim
Digital solutions save lives

Digital solutions save lives

Michael Schmelmer explains how digital solutions shape the future of Boehringer Ingelheim and the entire healthcare industry.
Patient Organizations

Patient Organizations

Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.